Molecular structure of Siguazodan, CAS Number: 115344-47-3
Siguazodan (CAS 115344-47-3)
Alternate Names:
N-Cyano-N′-methyl-N′′-[4-(1,4,5,6-tetrahydro-4-methyl-6 -oxo-3-pyridazinyl)phenyl]guanidine
Application:
Siguazodan is A selective phosphodiesterase PDE III inhibitor and a potent inotropic agent
CAS Number:
115344-47-3
Purity:
≥98%
Molecular Weight:
284.3
Molecular Formula:
C14H16N6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Siguazodan is a selective inhibitor of PDE (phosphodiesterase 3, PDE3) with an IC50 = 0.7 μM. This compound is a potent inotropic and vasodilator, with additional antiplatelet activity. Siguazodan has been shown to synergize with PDE4 inhibitors in blocking antigen-induced bronchospasm in cell models.
Siguazodan (CAS 115344-47-3) References
- Comparison of responses to siguazodan, rolipram, and zaprinast in the feline pulmonary vascular bed. | De Witt, BJ., et al. 2000. Eur J Pharmacol. 406: 233-8. PMID: 11020486
- Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. | Bardou, M., et al. 2001. J Cardiovasc Pharmacol. 38: 325-34. PMID: 11483882
- The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. | Murray, KJ., et al. 1990. Br J Pharmacol. 99: 612-6. PMID: 2158847
- Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells. | BinMahfouz, H., et al. 2015. Mol Pharmacol. 87: 64-76. PMID: 25324049
- In vivo pharmacological studies with SK&F 94836, a potent inotrope/vasodilator with a sustained duration of action. | Gristwood, RW., et al. 1988. Br J Pharmacol. 93: 893-901. PMID: 3390657
- Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. | Tang, KM., et al. 1994. Eur J Pharmacol. 268: 105-14. PMID: 7925608
- Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside. | Turner, NC., et al. 1994. Br J Pharmacol. 111: 1047-52. PMID: 8032589
- Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. | Underwood, DC., et al. 1994. J Pharmacol Exp Ther. 270: 250-9. PMID: 8035322
- Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi. | Qian, Y., et al. 1994. Eur Respir J. 7: 306-10. PMID: 8162984
- Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside. | Qian, Y., et al. 1993. Br J Pharmacol. 109: 774-8. PMID: 8358572
- The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum. | Tomkinson, A. and Raeburn, D. 1996. Br J Pharmacol. 118: 2131-9. PMID: 8864552
- Phosphodiesterase inhibitors suppress alpha2-adrenoceptor-mediated 5-hydroxytryptamine release from tracheae of newborn rabbits. | Freitag, A., et al. 1998. Eur J Pharmacol. 354: 67-71. PMID: 9726632
- The potential roles of cytokines, IL-5 and IL-8, and plasma cortisol in the anti-inflammatory actions of phosphodiesterase inhibitors in sensitized guinea-pig airways. | Danahay, H., et al. 1997. Pulm Pharmacol Ther. 10: 277-85. PMID: 9778491
Inhibitor of:
PDE.Activator of:
ARMC4, CapZIP, LHR, and PTG.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Siguazodan, 5 mg | sc-201201 | 5 mg | $100.00 | |||
Siguazodan, 25 mg | sc-201201A | 25 mg | $398.00 |